Neurocrine Jumps 15% on Third Straight Double Beat and Second Ingrezza Guidance Hike
NBIX sits 38% above its 52-week low of $122.138 on elevated volume (2.1× avg).
Summary
Neurocrine posted Q3 revenue of $1.1B, up about 41% year over year and $80M above consensus, with non-GAAP EPS of $3.29 beating by $0.54. That is the third consecutive double beat. Management raised 2026 Ingrezza sales guidance for the second time this year, to $2.9B-$2.925B from $2.83B-$2.88B, topping the $2.86B consensus. The stock is up more than 15% intraday, its biggest one-day gain in six years, following the 8-K and 10-Q filed last night. Diversification is showing: Crenessity and Vykat XR accounted for 28% of Q3 revenue, and Stifel lifted its target to $217 from $215 while Wedbush held $186. The open question is whether the Ingrezza raise holds as the franchise matures and generic pressure builds.
At the time of this announcement, NBIX was trading at $168.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.1B. The 52-week trading range was $122.14 to $186.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.